Sarepta Therapeutics Inc  

(Public, NASDAQ:SRPT)   Watch this stock  
Find more results for NASDAQ:AVII
13.70
+0.20 (1.48%)
Real-time:   10:54AM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 13.55 - 13.87
52 week 12.58 - 40.00
Open 13.80
Vol / Avg. 212,965.00/1.31M
Mkt cap 565.95M
P/E     -
Div/yield     -
EPS -2.54
Shares 41.31M
Beta 0.56
Inst. own 64%
Feb 25, 2015
Q4 2014 Sarepta Therapeutics Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Dec 10, 2014
Sarepta Therapeutics Inc at Oppenheimer Healthcare Conference
Dec 2, 2014
Sarepta DMD Community Update - Webcast
Dec 1, 2014
Sarepta Therapeutics Inc at Deutsche Bank BioFEST
Nov 19, 2014
Sarepta Therapeutics Inc at Stifel Healthcare Conference - Webcast
Nov 11, 2014
Sarepta Therapeutics Inc at Credit Suisse Healthcare Conference - Webcast
Nov 6, 2014
Q3 2014 Sarepta Therapeutics Inc Earnings Release
Nov 6, 2014
Q3 2014 Sarepta Therapeutics Inc Earnings Call - Webcast
Oct 27, 2014
Sarepta Therapeutics Announces Regulatory Update on Eteplirsen Conference Call - Webcast
Oct 1, 2014
Sarepta Therapeutics Inc at Leerink Rare Disease Roundtable - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -2759.77% -787.57%
Operating margin -3179.89% -634.95%
EBITD margin - -625.97%
Return on average assets -35.72% -45.10%
Return on average equity -40.00% -60.39%
Employees 146 -
CDP Score - -

Address

SUITE 415, 215 FIRST STREET
CAMBRIDGE, MA 02142
United States - Map
+1-617-2744000 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha

Description

Sarepta Therapeutics Inc. (Sarepta), formerly AVI BioPharma, Inc., is a biopharmaceutical company focused on the discovery and development of ribonucleic acid (RNA)-based therapeutics for the treatment of rare and infectious diseases. The Company has classified its drug development programs as Duchenne Muscular Dystrophy (DMD) and Infectious Disease Programs. The Company�s Duchenne muscular dystrophy (DMD) is primarily focused on its lead product candidate, Eteplirsen. The Company has completed a Phase IIb clinical trial for Eteplirsen. The Company, under its infectious disease programs, is primarily focused on development of a drug candidate for the Marburg hemorrhagic fever virus. The Company�s infectious disease programs is largely funded and supported by the U.S. Department of Defense (DoD).

Officers and directors

John C. Hodgman Interim Chairman of the Board
Age: 59
Bio & Compensation  - Reuters
Christopher Garabedian President, Chief Executive Officer, Director
Age: 47
Bio & Compensation  - Reuters
Sandesh Mahatme Chief Financial Officer, Senior Vice President, Chief Accounting Officer
Age: 49
Bio & Compensation  - Reuters
David Tyronne Howton Senior Vice President, General Counsel, Corporate Secretary
Age: 42
Bio & Compensation  - Reuters
Jayant Aphale Ph.D. Senior Vice President - Technical Operations
Age: 53
Bio & Compensation  - Reuters
Edward M. Kaye M.D. Senior Vice President, Chief Medical Officer
Age: 65
Bio & Compensation  - Reuters
M. Kathleen Behrens Ph.D. Independent Director
Age: 61
Bio & Compensation  - Reuters
Anthony R. Chase Independent Director
Bio & Compensation  - Reuters
Gil Price M.D. Independent Director
Age: 58
Bio & Compensation  - Reuters
Hans Wigzell M.D., Ph.D. Independent Director
Age: 76
Bio & Compensation  - Reuters